SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer

Trial Profile

SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 May 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; LHRH receptor agonists; LHRH receptor antagonists
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SENSI-CAB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01978873).
    • 07 Nov 2013 Planned end date changed from 2 Nov 2018 to 1 Nov 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top